Primary Site >> Pancreatic Cancer
Gene >> MAP2K7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Activation of MAP kinase cascade induced by human pancreatic phospholipase A2 in a human pancreatic cancer cell line. PMID: 9175881 |
Ref: Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression. PMID: 10402237 |
Ref: Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration. PMID: 10871844 Ref: MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. PMID: 10972974 |
Ref: Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. PMID: 11162624 Ref: Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions. PMID: 11286473 Ref: Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. PMID: 11358848 Ref: MEK/ERK-mediated proliferation is negatively regulated by P38 map kinase in the human pancreatic cancer cell line, PANC-1. PMID: 11401480 Ref: 12-lipoxygenase metabolite 12(S)-HETE stimulates human pancreatic cancer cell proliferation via protein tyrosine phosphorylation and ERK activation. PMID: 11745456 |
Ref: Enhancement of anchorage-independent growth of human pancreatic carcinoma MIA PaCa-2 cells by signaling from protein kinase C to mitogen-activated protein kinase. PMID: 12203369 Ref: Activation of conventional PKC isoforms increases expression of the pro-apoptotic protein Bad and TRAIL receptors. PMID: 12794242 |
Ref: Modified radiosensitivity of pancreatic cancer xenografts by farnesyl protein transferase inhibitor and MEK inhibitor. PMID: 12883735 Ref: MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac. PMID: 14576498 Ref: Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis. PMID: 14598883 Ref: CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). PMID: 14613031 Ref: Multiple signal pathways are involved in the mitogenic effect of 5(S)-HETE in human pancreatic cancer. PMID: 14707447 |
Ref: Involvement of the mitogen-activated protein kinase kinase 2 in the induction of cell dissociation in pancreatic cancer. PMID: 14654942 Ref: Activation and role of MAP kinases in 15d-PGJ2-induced apoptosis in the human pancreatic cancer cell line MIA PaCa-2. PMID: 15028947 Ref: Analysis of invasion-metastasis mechanism in pancreatic cancer: involvement of tight junction transmembrane protein occludin and MEK/ERK signal transduction pathway in cancer cell dissociation. PMID: 15069537 Ref: Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. PMID: 15073105 Ref: Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. PMID: 15483017 Ref: Relationship between activation of epidermal growth factor receptor and cell dissociation in pancreatic cancer. PMID: 15492819 Ref: Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. PMID: 15572689 |
Ref: Neurotensin and EGF induce synergistic stimulation of DNA synthesis by increasing the duration of ERK signaling in ductal pancreatic cancer cells. PMID: 15389644 Ref: CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. PMID: 15670977 Ref: Involvement of matrix metalloproteinase-7 in invasion-metastasis through induction of cell dissociation in pancreatic cancer. PMID: 15809719 Ref: Involvement of MEK-ERK signaling pathway in the inhibition of cell growth by troglitazone in human pancreatic cancer cells. PMID: 15896303 Ref: Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. PMID: 16009947 Ref: LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. PMID: 16105664 Ref: Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEK-ERK signal transduction pathway. PMID: 16311341 |
Ref: Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38. PMID: 16257181 Ref: MUC5AC mucin gene regulation in pancreatic cancer cells. PMID: 16773182 Ref: On the mechanisms of 12-O-tetradecanoylphorbol-13-acetate-induced growth arrest in pancreatic cancer cells. PMID: 16868480 Ref: Novel targets in solid tumors: MEK inhibitors. PMID: 17143253 |
Ref: Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. PMID: 17043657 Ref: BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. PMID: 17097223 Ref: Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. PMID: 17353198 Ref: Analysis of CCN2 promoter activity in PANC-1 cells: regulation by ras/MEK/ERK. PMID: 18481199 |
Ref: Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies. PMID: 18049840 Ref: PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. PMID: 18343945 Ref: MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth. PMID: 18346844 Ref: ANTI-ADHESION evolves to a promising therapeutic concept in oncology. PMID: 18393855 Ref: High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma. PMID: 18473350 Ref: Biologic therapies for advanced pancreatic cancer. PMID: 18699769 Ref: Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. PMID: 19001434 Ref: New treatment options for advanced pancreatic cancer. PMID: 19072345 |
Ref: HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. PMID: 19179606 Ref: Comparison of ras-responsive gene enhancers in pancreatic tumor cells that express either wild-type or mutant K-ras. PMID: 19254697 Ref: Death of a tumor: targeting CCN in pancreatic cancer. PMID: 19267221 Ref: Troglitazone increases expression of E-cadherin and claudin 4 in human pancreatic cancer cells. PMID: 19285010 Ref: Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. PMID: 19288493 Ref: KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. PMID: 19372556 Ref: Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells. PMID: 19540829 Ref: Up-regulation of Kruppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha. PMID: 19671674 Ref: Activation of two distinct MAPK pathways governs constitutive expression of matrix metalloproteinase-1 in human pancreatic cancer cell lines. PMID: 19885545 Ref: Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. PMID: 20009539 Ref: [Over-expression of caveolin-1 inhibits proliferation and invasion of pancreatic carcinoma cells in vitro]. PMID: 20021823 |
Ref: Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53. PMID: 19609950 Ref: Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis. PMID: 20179210 Ref: Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways. PMID: 20301194 Ref: Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. PMID: 20642839 Ref: MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells. PMID: 20669973 Ref: Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts. PMID: 20920162 Ref: TLN-4601 suppresses growth and induces apoptosis of pancreatic carcinoma cells through inhibition of Ras-ERK MAPK signaling. PMID: 21044336 Ref: Analysis of invasion-metastasis in pancreatic cancer: Correlation between the expression and arrangement of tight junction protein-2 and cell dissociation in pancreatic cancer cells. PMID: 21472214 |
Ref: A novel activity from an old compound: Manzamine A reduces the metastatic potential of AsPC-1 pancreatic cancer cells and sensitizes them to TRAIL-induced apoptosis. PMID: 20352293 Ref: Stem cell factor/c-kit signaling enhances invasion of pancreatic cancer cells via HIF-1alpha under normoxic condition. PMID: 21320746 Ref: Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. PMID: 21385921 Ref: Silencing of BNIP3 results from promoter methylation by DNA methyltransferase 1 induced by the mitogen-activated protein kinase pathway. PMID: 21573703 Ref: Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway. PMID: 21723941 Ref: Resveratrol inhibits growth of orthotopic pancreatic tumors through activation of FOXO transcription factors. PMID: 21980390 Ref: Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD lenalidomide. PMID: 22110196 Ref: Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells. PMID: 24048788 |
Ref: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. PMID: 21594619 Ref: Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma. PMID: 22222635 Ref: Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. PMID: 22411900 Ref: Transforming growth factor beta and Ras/MEK/ERK signaling regulate the expression level of a novel tumor suppressor Lefty. PMID: 22441145 Ref: New tools and novel approaches in treating locally advanced pancreatic adenocarcinoma. PMID: 22797388 Ref: Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity. PMID: 22833572 Ref: Reduced expression of Raf kinase inhibitor protein correlates with poor prognosis in pancreatic cancer. PMID: 22855160 Ref: K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PMID: 22952903 Ref: Transcriptional regulation of the interleukin-11 gene by oncogenic Ras. PMID: 23027619 Ref: Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach. PMID: 23180942 |
Ref: Grape seed proanthocyanidins inhibit migration potential of pancreatic cancer cells by promoting mesenchymal-to-epithelial transition and targeting NF-kappaB. PMID: 22902508 Ref: Collagen triple helix repeat containing-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells. PMID: 23222813 Ref: Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells. PMID: 23340175 Ref: Suppression of Lefty expression in induced pluripotent cancer cells. PMID: 23407711 Ref: Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. PMID: 23441129 Ref: Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models. PMID: 23475955 Ref: Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. PMID: 23497499 Ref: Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. PMID: 23530240 Ref: A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. PMID: 23583440 Ref: Direct TGF-beta1 signaling between activated platelets and pancreatic cancer cells primes cisplatin insensitivity. PMID: 23584798 Ref: Modulation of pancreatic tumor potential by overexpression of protein kinase C beta1. PMID: 23695799 Ref: Activated PAR-2 regulates pancreatic cancer progression through ILK/HIF-alpha-induced TGF-alpha expression and MEK/VEGF-A-mediated angiogenesis. PMID: 23764046 Ref: Novel agents and future prospects in the treatment of pancreatic adenocarcinoma. PMID: 23846936 Ref: Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. PMID: 23918833 Ref: miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells. PMID: 23973710 Ref: Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. PMID: 24130864 Ref: Transcriptional regulation of Delta6-desaturase by peroxisome proliferative-activated receptor delta agonist in human pancreatic cancer cells: role of MEK/ERK1/2 pathway. PMID: 24294133 Ref: Effect of inhibition of MEK pathway on 5-aza-deoxycytidine-suppressed pancreatic cancer cell proliferation. PMID: 24301926 Ref: Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC). PMID: 24330423 Ref: The MEK/ERK pathway promotes NOTCH signalling in pancreatic cancer cells. PMID: 24392017 Ref: Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer. PMID: 24403857 |
Ref: Up-regulated cten by FGF2 contributes to FGF2-mediated cell migration. PMID: 23625726 Ref: Target therapies in pancreatic carcinoma. PMID: 23992319 Ref: microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-beta actions. PMID: 24096486 Ref: Overexpression of calreticulin contributes to the development and progression of pancreatic cancer. PMID: 24264800 Ref: The ErbB/HER family of protein-tyrosine kinases and cancer. PMID: 24269963 Ref: Pancreatic cancer-associated retinoblastoma 1 dysfunction enables TGF-beta to promote proliferation. PMID: 24334458 Ref: Impaired JNK signaling cooperates with KrasG12D expression to accelerate pancreatic ductal adenocarcinoma. PMID: 24713432 Ref: HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. PMID: 24819705 Ref: Rasfonin, a novel 2-pyrone derivative, induces ras-mutated Panc-1 pancreatic tumor cell death in nude mice. PMID: 24853419 Ref: A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. PMID: 24915778 Ref: Functional p38 MAPK identified by biomarker profiling of pancreatic cancer restrains growth through JNK inhibition and correlates with improved survival. PMID: 24963048 Ref: Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer. PMID: 25117978 Ref: CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. PMID: 25156567 Ref: KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. PMID: 25167228 Ref: Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. PMID: 25266736 Ref: Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer. PMID: 25271986 Ref: Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway. PMID: 25382779 Ref: Dynamic distribution of ERK, p38 and JNK during the development of pancreatic ductal adenocarcinoma. PMID: 25440531 |
Ref: A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. PMID: 25344362 Ref: Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. PMID: 25348516 Ref: Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer. PMID: 25376606 Ref: The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK/ERK inhibitor AZD-6244. PMID: 25498501 Ref: A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. PMID: 25500057 Ref: Effect of PPARdelta agonist on stearoyl-CoA desaturase 1 in human pancreatic cancer cells: role of MEK/ERK1/2 pathway. PMID: 25575964 Ref: Inhibition of EP2/EP4 signaling abrogates IGF-1R-mediated cancer cell growth: involvement of protein kinase C-theta activation. PMID: 25638159 Ref: Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. PMID: 25673820 Ref: Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor. PMID: 25766633 Ref: N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. PMID: 25897431 Ref: Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells. PMID: 25961376 Ref: The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1). PMID: 26228206 Ref: Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. PMID: 26257206 Ref: Repression of CD24 surface protein expression by oncogenic Ras is relieved by inhibition of Raf but not MEK or PI3K. PMID: 26301220 Ref: MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways. PMID: 26505547 |
Ref: A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. PMID: 26251290 Ref: RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. PMID: 26350096 Ref: Genomic Loss of DUSP4 Contributes to the Progression of Intraepithelial Neoplasm of Pancreas to Invasive Carcinoma. PMID: 26941286 Ref: Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. PMID: 27041411 Ref: A combinatorial strategy for treating KRAS-mutant lung cancer. PMID: 27338794 Ref: Selective GPR55 antagonism reduces chemoresistance in cancer cells. PMID: 27423937 Ref: Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma. PMID: 27435925 Ref: KRAS-related proteins in pancreatic cancer. PMID: 27595930 Ref: MEK Inhibitor Suppresses Expression of the miR-17-92 Cluster with G1-Phase Arrest in HT-29 Human Colon Cancer Cells and MIA PaCa-2 Pancreatic Cancer Cells. PMID: 27630293 Ref: Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras. PMID: 27634878 Ref: Leukotriene B4 induces EMT and vimentin expression in PANC-1 pancreatic cancer cells: Involvement of BLT2 via ERK2 activation. PMID: 27914516 |
Ref: Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. PMID: 27978579 Ref: Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells. PMID: 28060183 Ref: Mitogen-activated Protein Kinase Kinase Activity Maintains Acinar-to-Ductal Metaplasia and Is Required for Organ Regeneration in Pancreatitis. PMID: 28090569 Ref: ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition. PMID: 28178529 Ref: Emerging protein kinase inhibitors for treating pancreatic cancer. PMID: 28253828 Ref: MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX). PMID: 28537897 Ref: Pancreatic cancer heterogeneity and response to Mek inhibition. PMID: 28581516 Ref: KIF15 promotes pancreatic cancer proliferation via the MEK-ERK signalling pathway. PMID: 28595260 Ref: Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma. PMID: 28619758 Ref: Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction. PMID: 28720574 Ref: A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. PMID: 28746882 Ref: Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers. PMID: 28957417 Ref: Negative regulation of TGF-beta1-induced MKK6-p38 and MEK-ERK signalling and epithelial-mesenchymal transition by Rac1b. PMID: 29229918 Ref: The Role of PAR2 in TGF-beta1-Induced ERK Activation and Cell Motility. PMID: 29261154 Ref: The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors. PMID: 29507555 |
Ref: p38 differentially regulates ERK, p21, and mitogenic signalling in two pancreatic carcinoma cell lines. PMID: 29380233 Ref: Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. PMID: 29435178 Ref: RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. PMID: 29436617 Ref: MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models. PMID: 29545922 Ref: A novel tricarbonylmethane agent (CMC2.24) reduces human pancreatic tumor growth in mice by targeting Ras. PMID: 29683208 Ref: ROS mediated EGFR/MEK/ERK/HIF-1alpha Loop Regulates Glucose metabolism in pancreatic cancer. PMID: 29702094 Ref: A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. PMID: 29757973 Ref: Inhibition of pancreatic cancer Panc1 cell migration by omeprazole is dependent on aryl hydrocarbon receptor activation of JNK. PMID: 29758193 Ref: MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. PMID: 29857821 Ref: Rapid induction of pancreatic cancer cells to cancer stem cells via heterochromatin modulation. PMID: 30045656 Ref: KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. PMID: 30217561 Ref: Tanshinone IIA can inhibit MiaPaCa2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways. PMID: 30226540 Ref: Cyclooxygenase-2 Influences Response to Co-Targeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers. PMID: 30254182 Ref: Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-2-regulated apoptosis in pancreatic cancer cells. PMID: 30261145 Ref: The long coding RNA AFAP1-AS1 promotes tumor cell growth and invasion in pancreatic cancer through upregulating the IGF1R oncogene via sequestration of miR-133a. PMID: 30300116 Ref: CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. PMID: 30323222 Ref: Isorhamnetin suppresses PANC-1 pancreatic cancer cell proliferation through S phase arrest. PMID: 30372904 Ref: Laparoscopic pancreaticoduodenectomy for metastatic pancreatic melanoma: A case report. PMID: 30383642 |